Christine Fox is VP at TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA). They have made 3 open-market trades across 1 company since 2024, most recently 2026-04-30.
CIK 0001998173
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TEVA | 63,647 | $2.6M |
Shares reported on the most recent Form 4, priced at the 2026-05-04 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TEVA | SELL | 2026-04-30 | 2026-05-04 | $35.31 | $751K | -0.4% | -7.4% | -2.9% |
| TEVA | SELL · 10b5-1 | 2026-03-05 | 2026-03-09 | $31.67 | $251K | -6.2% | -2.7% | +6.0% |
| TEVA | SELL | 2026-03-04 | 2026-03-06 | $32.46 | $295K | -3.0% | -2.3% | +12.7% |
| TEVA | SELL · 10b5-1 | 2025-11-20 | 2025-11-24 | $24.78 | $1.4M | +14.0% | +27.1% | +35.8% |
| TEVA | SELL | 2025-11-14 | 2025-11-18 | $25.11 | $753K | +7.0% | +21.4% | +37.8% |
| TEVA | SELL · 10b5-1 | 2025-03-04 | 2025-03-06 | $15.77 | $161K | +7.2% | -9.4% | +13.9% |
| TEVA | SELL · 10b5-1 | 2024-11-20 | 2024-11-21 | $16.87 | $654K | +4.3% | +30.1% | +0.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.